Valuation: Fortress Biotech, Inc.

Market Cap 11Cr 9.74Cr 9.06Cr 8.32Cr 16Cr 1.07TCr 16Cr 107.61Cr 42Cr 525.3Cr 42Cr 41Cr 1.82TCr P/E 2026 *
1.39x
P/E 2027 * -6.68x
Enterprise Value 11Cr 9.74Cr 9.06Cr 8.32Cr 16Cr 1.07TCr 16Cr 107.61Cr 42Cr 525.3Cr 42Cr 41Cr 1.82TCr EV / Sales 2026 *
1.39x
EV / Sales 2027 * 0.9x
Free-Float
77.21%
Yield 2026 *
-
Yield 2027 * -
1 day-2.62%
1 week-0.60%
Current month+9.15%
1 month+6.37%
3 months+43.35%
6 months-1.76%
Current year-8.74%
1 week 3.27
Extreme 3.27
3.65
1 month 2.7
Extreme 2.7
3.84
Current year 2.18
Extreme 2.18
4.53
1 year 1.77
Extreme 1.77
4.53
3 years 1.24
Extreme 1.24
9
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
22/06/26 Free

Chief Financial Officer

4,00,000 1.2041%
01/04/26 Free

Chief Financial Officer

2,967 0.0096%
18/03/26 Free

Chief Executive Officer

4,75,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-2.62%-0.60%+72.16%-65.48% 11Cr
+0.63%-3.06%+16.18%-9.78% 6.63TCr
+1.23%+2.80%+37.51%+202.14% 5.26TCr
+10.08%+51.80%+51.80%+51.80% 4.33TCr
-1.32%-7.38%-57.63%-57.10% 3.86TCr
+0.78%-1.84%+52.49%-27.01% 2.96TCr
+0.84%+0.36%+66.93%+85.42% 2.33TCr
-5.17%-12.54%+58.98%-56.04% 2.26TCr
-1.21%+1.12%+1.98%+170.93% 2.02TCr
-0.22%-0.95%+61.97%+123.78% 1.63TCr
Average +0.90%-1.24%+36.24%+41.87% 3.13TCr
Weighted average by Cap. +1.67%-0.40%+27.37%+49.22%

Financials

2026 *2027 *
Net sales 7.99Cr 7.02Cr 6.52Cr 5.99Cr 11Cr 769.21Cr 11Cr 77Cr 30Cr 378.17Cr 30Cr 29Cr 1.31TCr 12Cr 11Cr 10Cr 9.22Cr 17Cr 1.18TCr 18Cr 119.3Cr 47Cr 582.34Cr 46Cr 45Cr 2.01TCr
Net income 9.05Cr 7.95Cr 7.39Cr 6.78Cr 13Cr 871.64Cr 13Cr 88Cr 34Cr 428.53Cr 34Cr 33Cr 1.48TCr -2.08Cr -1.83Cr -1.7Cr -1.56Cr -2.93Cr -200.67Cr -2.98Cr -20Cr -7.9Cr -99Cr -7.82Cr -7.65Cr -341.11Cr
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
24/26/24 $3.340 -2.62% 4,14,439
23/26/23 $3.430 -3.38% 4,45,373
22/26/22 $3.550 +0.57% 6,04,713
21/26/21 $3.530 +6.01% 5,57,289
20/26/20 $3.330 -0.89% 4,88,560
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.340USD
Average target price
11.00USD
Spread / Average Target
+229.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock